Lima One
Purchase-Price Allocation
Goodwill
$61.1M
2 years of history · ending 2025-12-31 · SEC EDGAR
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.00% | 0.00% | 0.00% | -0.10% | 0.00% | 0.10% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | — | -0.60% | -0.20% | -0.30% |
| Valuation Allowance Change | -6.90% | -11.10% | -10.10% | -9.60% | -6.40% | 9.10% |
| Effective Tax Rate | -0.20% | 0.60% | 0.50% | 0.30% | 0.30% | -0.40% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $2.0M | $2.7M | −$851.0K | $278.0K | $443.0K | −$735.0K |
| Income Taxes Paid (Cash) | — | — | — | — | — | $564.0K |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$61.1M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).